Cargando…

Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs

Pyoderma gangrenosum (PG) is a relatively rare neutrophilic dermatosis presenting as a rapidly progressive and painful skin ulcer characterized by undermined borders and peripheral erythema. Immunosuppressive therapy is the first-line treatment for PG; however, large ulcers often take months or year...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimura, Mai, Mizutani, Kento, Yokota, Naho, Goto, Hiroyuki, Akeda, Tomoko, Kitagawa, Hiroshi, Habe, Koji, Hayashi, Akinobu, Yamanaka, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739536/
https://www.ncbi.nlm.nih.gov/pubmed/36498498
http://dx.doi.org/10.3390/jcm11236924
_version_ 1784847831105798144
author Nishimura, Mai
Mizutani, Kento
Yokota, Naho
Goto, Hiroyuki
Akeda, Tomoko
Kitagawa, Hiroshi
Habe, Koji
Hayashi, Akinobu
Yamanaka, Keiichi
author_facet Nishimura, Mai
Mizutani, Kento
Yokota, Naho
Goto, Hiroyuki
Akeda, Tomoko
Kitagawa, Hiroshi
Habe, Koji
Hayashi, Akinobu
Yamanaka, Keiichi
author_sort Nishimura, Mai
collection PubMed
description Pyoderma gangrenosum (PG) is a relatively rare neutrophilic dermatosis presenting as a rapidly progressive and painful skin ulcer characterized by undermined borders and peripheral erythema. Immunosuppressive therapy is the first-line treatment for PG; however, large ulcers often take months or years to heal. Surgical treatments, such as negative pressure wound therapy (NPWT) and skin grafting, are still controversial due to the risk of inducing the pathergy phenomenon and eliciting PG development by traumatic factors. Herein, we report on four cases of PG treated with skin grafting, with or without NPWT, under the control of immunosuppressive drugs at our institution. All cases adapted well, but one case showed recurrence at the periphery of the grafted area five months postoperatively. The current patients were treated with the following doses of oral prednisolone (PSL): PSL 10 mg daily, PSL 5 mg daily + adalimumab 40 mg/week, PSL 12 mg + 6 mg of tacrolimus daily, and PSL 20 mg daily during skin grafting. No severe complications, including infections, were observed. Surgical treatments, such as skin grafting with or without NPWT, may accelerate wound healing, shorten the administration of analgesics and long-term immunosuppressive therapy, and reduce the risk of infection.
format Online
Article
Text
id pubmed-9739536
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97395362022-12-11 Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs Nishimura, Mai Mizutani, Kento Yokota, Naho Goto, Hiroyuki Akeda, Tomoko Kitagawa, Hiroshi Habe, Koji Hayashi, Akinobu Yamanaka, Keiichi J Clin Med Case Report Pyoderma gangrenosum (PG) is a relatively rare neutrophilic dermatosis presenting as a rapidly progressive and painful skin ulcer characterized by undermined borders and peripheral erythema. Immunosuppressive therapy is the first-line treatment for PG; however, large ulcers often take months or years to heal. Surgical treatments, such as negative pressure wound therapy (NPWT) and skin grafting, are still controversial due to the risk of inducing the pathergy phenomenon and eliciting PG development by traumatic factors. Herein, we report on four cases of PG treated with skin grafting, with or without NPWT, under the control of immunosuppressive drugs at our institution. All cases adapted well, but one case showed recurrence at the periphery of the grafted area five months postoperatively. The current patients were treated with the following doses of oral prednisolone (PSL): PSL 10 mg daily, PSL 5 mg daily + adalimumab 40 mg/week, PSL 12 mg + 6 mg of tacrolimus daily, and PSL 20 mg daily during skin grafting. No severe complications, including infections, were observed. Surgical treatments, such as skin grafting with or without NPWT, may accelerate wound healing, shorten the administration of analgesics and long-term immunosuppressive therapy, and reduce the risk of infection. MDPI 2022-11-24 /pmc/articles/PMC9739536/ /pubmed/36498498 http://dx.doi.org/10.3390/jcm11236924 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Nishimura, Mai
Mizutani, Kento
Yokota, Naho
Goto, Hiroyuki
Akeda, Tomoko
Kitagawa, Hiroshi
Habe, Koji
Hayashi, Akinobu
Yamanaka, Keiichi
Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs
title Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs
title_full Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs
title_fullStr Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs
title_full_unstemmed Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs
title_short Treatment Strategy for Pyoderma Gangrenosum: Skin Grafting with Immunosuppressive Drugs
title_sort treatment strategy for pyoderma gangrenosum: skin grafting with immunosuppressive drugs
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739536/
https://www.ncbi.nlm.nih.gov/pubmed/36498498
http://dx.doi.org/10.3390/jcm11236924
work_keys_str_mv AT nishimuramai treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs
AT mizutanikento treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs
AT yokotanaho treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs
AT gotohiroyuki treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs
AT akedatomoko treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs
AT kitagawahiroshi treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs
AT habekoji treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs
AT hayashiakinobu treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs
AT yamanakakeiichi treatmentstrategyforpyodermagangrenosumskingraftingwithimmunosuppressivedrugs